Online inquiry

IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7524MR)

This product GTTS-WQ7524MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CLDN18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001002026.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51208
UniProt ID P56856
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7524MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2341MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ12764MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ7731MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ11586MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ11374MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ15709MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ6060MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ8510MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu3F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW